NRX Pharmaceuticals (NRXP) Stock News
$NRXP · NASDAQ · 1 stories in 30 days$2.80
1D +7.69%
BORSA has published 1 story on NRX Pharmaceuticals (NRXP) in the past 30 days. BORSA’s news read on NRXP is bullish at 67/100, based on 1 company event over the past 7 days. NRX Pharmaceuticals’ next earnings report is scheduled for Friday, Nov 13.
The wire on $NRXP
newest first · updated · direct subject stories onlyNRx Pharmaceuticals completes manufacturing validation for preservative-free ketamine ahead of FDA goal date
NRx Pharmaceuticals (NRXP) announced completion of three process validation lots and two-year room-temperature stability data for its preservative-free ketamine. Commercial supply is on hand pending ANDA approval. The FDA GDUFA goal date is November 10, 2026.
bullish 75 · impact 60The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.
BORSAPLUSNews on Price · Earnings read · Flow and ownership · Options context
Create a free account · no card NRX Pharmaceuticals (NRXP) stock: common questions
What is the latest NRX Pharmaceuticals stock news?
The highest-impact NRXP story BORSA published in the past 30 days:
· NRx Pharmaceuticals completes manufacturing validation for preservative-free ketamine ahead of FDA goal date